Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer

Statistical Methods for Survival Data Analysis.

Peter A. Lachenbruch, Elisa T. Lee · Journal of the American Statistical Association · 1993 · 2.9K citations

Public Health, Biostatistics, Survival Analysis +11

Some suggestions for measuring predictive performance

Lewis B. Sheiner, Stuart L. Beal · Journal of Pharmacokinetics and Biopharmaceutics · 1981 · 1.6K citations

Business, Business Analytics, Performance Assessment +8

Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up

G. Bonadonna, Pinuccia Valagussa, Angela Moliterni et al. · New England Journal of Medicine · 1995 · 1.1K citations

Medicine, Oncology, Pharmacology +17

Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction

Daniel B. Mark, Mark A. Hlatky, Robert M. Califf et al. · New England Journal of Medicine · 1995 · 524 citations · Full text

Medicine, Cardiology, Pharmacoeconomics +14

Ondansetron Compared with Dexamethasone and Metoclopramide as Antiemetics in the Chemotherapy of Breast Cancer with Cyclophosphamide, Methotrexate, and Fluorouracil

Martin Levitt, David Warr, Louise Yelle et al. · New England Journal of Medicine · 1993 · 73 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9